GIBSON DUNN

Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics

Firm News | February 4, 2026

Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc. The Gibson Dunn finance team involved in the transaction was led by partner Jin Hee Kim and included associates Paul Rafla, Jaclyn Wang, Aliya Zuberi, and Ruoqi Wei. Partners Ryan Murr, Karen Spindler, and Meghan Hungate advised on licensing and intellectual property. Of counsel Carlo Felizardo and associate Michael Dziuban advised on FDA and regulatory matters. Partner Matt Donnelly, of counsel Kate Long, and associate Jason Zhang advised on tax aspects.

Related People

Jin Hee Kim

Paul Rafla

Jaclyn Wang

Aliya Zuberi

Ruoqi Wei

Ryan A. Murr

Karen A. Spindler

Meghan M. Hungate

Michael R. Dziuban

Kate Long

Related Capabilities

Finance

Intellectual Property

Life Sciences

FDA and Health Care

Tax

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**